Axcella Health Analyst Ratings
Axcella Health Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/02/2022 | 367.29% | Chardan Capital | $7 → $5 | Maintains | Buy |
| 10/03/2022 | 834.58% | HC Wainwright & Co. | $8 → $10 | Maintains | Buy |
| 08/03/2022 | 647.66% | HC Wainwright & Co. | $14 → $8 | Maintains | Buy |
| 08/03/2022 | 460.75% | SVB Leerink | $9 → $6 | Maintains | Outperform |
| 05/09/2022 | 554.21% | Chardan Capital | $12 → $7 | Maintains | Buy |
| 03/31/2022 | 741.12% | SVB Leerink | $10 → $9 | Maintains | Outperform |
| 11/16/2021 | 1021.5% | Chardan Capital | $10 → $12 | Maintains | Buy |
| 10/12/2021 | 460.75% | Noble Capital Markets | → $6 | Initiates Coverage On | → Outperform |
| 09/22/2021 | 367.29% | Goldman Sachs | $9 → $5 | Downgrades | Buy → Neutral |
| 07/30/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 07/06/2021 | 1208.41% | HC Wainwright & Co. | → $14 | Initiates Coverage On | → Buy |
| 06/03/2021 | 834.58% | Chardan Capital | $16 → $10 | Maintains | Buy |
| 10/27/2020 | 1395.33% | Chardan Capital | → $16 | Initiates Coverage On | → Buy |
| 10/26/2020 | 834.58% | SVB Leerink | → $10 | Assumes | → Outperform |
| 09/25/2020 | 1208.41% | B. Riley Securities | → $14 | Initiates Coverage On | → Buy |
| 08/06/2020 | 834.58% | SVB Leerink | $20 → $10 | Maintains | Outperform |
| 07/31/2020 | 2236.45% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 05/28/2020 | 2516.82% | Wedbush | → $28 | Initiates Coverage On | → Outperform |
| 05/18/2020 | 1769.16% | SVB Leerink | $21 → $20 | Maintains | Outperform |
| 05/01/2020 | 834.58% | BTIG | → $10 | Initiates Coverage On | → Buy |
| 11/15/2019 | 928.04% | JP Morgan | $20 → $11 | Maintains | Overweight |
| 06/03/2019 | 1769.16% | JP Morgan | → $20 | Initiates Coverage On | → Overweight |
| 06/03/2019 | 2236.45% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/02/2022 | 367.29% | 查丹资本 | 7 美元 → 5 美元 | 维护 | 买 |
| 2022 年 3 月 10 日 | 834.58% | HC Wainwright & Co. | 8 美元 → 10 美元 | 维护 | 买 |
| 08/03/2022 | 647.66% | HC Wainwright & Co. | 14 美元 → 8 美元 | 维护 | 买 |
| 08/03/2022 | 460.75% | SVB Leerink | 9 美元 → 6 美元 | 维护 | 跑赢大盘 |
| 05/09/2022 | 554.21% | 查丹资本 | 12 美元 → 7 美元 | 维护 | 买 |
| 03/31/2022 | 741.12% | SVB Leerink | 10 美元 → 9 美元 | 维护 | 跑赢大盘 |
| 11/16/2021 | 1021.5% | 查丹资本 | 10 美元 → 12 美元 | 维护 | 买 |
| 2021 年 12 月 10 日 | 460.75% | 贵族资本市场 | → 6 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 9 月 22 日 | 367.29% | 高盛 | 9 美元 → 5 美元 | 降级 | 买入 → 中性 |
| 07/30/2021 | — | 摩根大通 | 降级 | 中性 → 体重不足 | |
| 2021 年 6 月 7 日 | 1208.41% | HC Wainwright & Co. | → 14 美元 | 启动覆盖范围开启 | → 购买 |
| 06/03/2021 | 834.58% | 查丹资本 | 16 美元 → 10 美元 | 维护 | 买 |
| 10/27/2020 | 1395.33% | 查丹资本 | → 16 美元 | 启动覆盖范围开启 | → 购买 |
| 10/26/2020 | 834.58% | SVB Leerink | → 10 美元 | 假设 | → 跑赢大盘 |
| 2020 年 9 月 25 日 | 1208.41% | B. 莱利证券 | → 14 美元 | 启动覆盖范围开启 | → 购买 |
| 08/06/2020 | 834.58% | SVB Leerink | 20 美元 → 10 美元 | 维护 | 跑赢大盘 |
| 07/31/2020 | 2236.45% | 派珀·桑德勒 | → 25 美元 | 启动覆盖范围开启 | → 超重 |
| 05/28/2020 | 2516.82% | Wedbush | → 28 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2020 年 5 月 18 日 | 1769.16% | SVB Leerink | 21 美元 → 20 美元 | 维护 | 跑赢大盘 |
| 05/01/2020 | 834.58% | BTIG | → 10 美元 | 启动覆盖范围开启 | → 购买 |
| 11/15/2019 | 928.04% | 摩根大通 | 20 美元 → 11 美元 | 维护 | 超重 |
| 06/03/2019 | 1769.16% | 摩根大通 | → 20 美元 | 启动覆盖范围开启 | → 超重 |
| 06/03/2019 | 2236.45% | 高盛 | → 25 美元 | 启动覆盖范围开启 | → 购买 |
Axcella Health Questions & Answers
Axcella 健康问题与解答
The latest price target for Axcella Health (NASDAQ: AXLA) was reported by Chardan Capital on November 2, 2022. The analyst firm set a price target for $5.00 expecting AXLA to rise to within 12 months (a possible 367.29% upside). 7 analyst firms have reported ratings in the last year.
查丹资本于2022年11月2日公布了Axcella Health（纳斯达克股票代码：AXLA）的最新目标股价。该分析公司将目标股价定为5.00美元，预计AXLA将在12个月内升至12个月内（可能上涨367.29％）。去年有7家分析公司公布了评级。
The latest analyst rating for Axcella Health (NASDAQ: AXLA) was provided by Chardan Capital, and Axcella Health maintained their buy rating.
Chardan Capital对Axcella Health（纳斯达克股票代码：AXLA）的最新分析师评级由Chardan Capital提供，Axcella Health维持买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axcella Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axcella Health was filed on November 2, 2022 so you should expect the next rating to be made available sometime around November 2, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Axcella Health的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Axcella Health的最新评级是在2022年11月2日发布的，因此您应该预计下一个评级将在2023年11月2日左右公布。
While ratings are subjective and will change, the latest Axcella Health (AXLA) rating was a maintained with a price target of $7.00 to $5.00. The current price Axcella Health (AXLA) is trading at is $1.07, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Axcella Health（AXLA）评级保持不变，目标股价为7.00美元至5.00美元。Axcella Health（AXLA）目前的交易价格为1.07美元，超出了分析师的预期区间。